NewcelX Ltd.
NCEL | NASDAQ
$2.92
-$0.05 (-1.68%)
Sep 22, 2026, 3:04 PM ET · Market open
Company Profile
NewcelX Ltd., a biotechnology firm established in 2008 and based in Zurich, Switzerland, is dedicated to advancing groundbreaking therapeutic solutions. The company's focus lies in developing innovative treatments, utilizing both cell-based and small-molecule approaches, to address challenging neurodegenerative and metabolic diseases.
Key Executives
| Name | Position |
|---|---|
| Ronen Twito | Chief Executive Officer & Executive Chairman |
| Omri Hagai | Chief Financial Officer |
| Alexander Zwyer | Chief Business Officer & Executive Director |
| Ariel Revel | Director of Medical Affairs |
| Eric Konofal | Head of Doxa Program |
| Michel Revel | Co-Founder, Chief Scientist, Head of the Scientific Advisory Board & Director |
| Yossi Ben-Yossef | Honorary President & Strategic Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 26, 2026 | EFFECT | Filing |
| Aug 24, 2026 | D | Filing |
| Aug 20, 2026 | F-3 | Filing |
| Aug 03, 2026 | 6-K | Filing |
| Jul 31, 2026 | 6-K | Filing |
| Jul 15, 2026 | 6-K | Filing |
| Jul 08, 2026 | 6-K | Filing |
| Jul 01, 2026 | 6-K | Filing |
| Jun 30, 2026 | 6-K | Filing |
| Jun 17, 2026 | EFFECT | Filing |
NewcelX Ltd.
| Country | Switzerland |
| IPO Date | Oct 23, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Ronen Twito |
Stock Details
| Ticker Symbol | NCEL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001783036 |
| CUSIP Number | H5835A109 |
| ISIN Number | CH1442297896 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove NCEL